BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 16272290)

  • 1. Enhancement of HIV-specific CD8 T cell responses by dual costimulation with CD80 and CD137L.
    Bukczynski J; Wen T; Wang C; Christie N; Routy JP; Boulassel MR; Kovacs CM; Macdonald KS; Ostrowski M; Sekaly RP; Bernard NF; Watts TH
    J Immunol; 2005 Nov; 175(10):6378-89. PubMed ID: 16272290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of OX40 ligand as a costimulator of human antiviral memory CD8 T cell responses: comparison with B7.1 and 4-1BBL.
    Serghides L; Bukczynski J; Wen T; Wang C; Routy JP; Boulassel MR; Sekaly RP; Ostrowski M; Bernard NF; Watts TH
    J Immunol; 2005 Nov; 175(10):6368-77. PubMed ID: 16272289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function.
    Wen T; Bukczynski J; Watts TH
    J Immunol; 2002 May; 168(10):4897-906. PubMed ID: 11994439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 4-1BBL induces TNF receptor-associated factor 1-dependent Bim modulation in human T cells and is a critical component in the costimulation-dependent rescue of functionally impaired HIV-specific CD8 T cells.
    Wang C; Wen T; Routy JP; Bernard NF; Sekaly RP; Watts TH
    J Immunol; 2007 Dec; 179(12):8252-63. PubMed ID: 18056369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy.
    Cannons JL; Lau P; Ghumman B; DeBenedette MA; Yagita H; Okumura K; Watts TH
    J Immunol; 2001 Aug; 167(3):1313-24. PubMed ID: 11466348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines.
    Kudo-Saito C; Hodge JW; Kwak H; Kim-Schulze S; Schlom J; Kaufman HL
    Vaccine; 2006 Jun; 24(23):4975-86. PubMed ID: 16621183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fighting with the enemy's weapons? the role of costimulatory molecules in HIV.
    De Keersmaecker B; Thielemans K; Aerts JL
    Curr Mol Med; 2011 Apr; 11(3):172-96. PubMed ID: 21375494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-15-dependent induction of 4-1BB promotes antigen-independent CD8 memory T cell survival.
    Pulle G; Vidric M; Watts TH
    J Immunol; 2006 Mar; 176(5):2739-48. PubMed ID: 16493029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Murine CD8 lymphocyte expansion in vitro by artificial antigen-presenting cells expressing CD137L (4-1BBL) is superior to CD28, and CD137L expressed on neuroblastoma expands CD8 tumour-reactive effector cells in vivo.
    Yan X; Johnson BD; Orentas RJ
    Immunology; 2004 May; 112(1):105-16. PubMed ID: 15096190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 4-1BB and OX40 act independently to facilitate robust CD8 and CD4 recall responses.
    Dawicki W; Bertram EM; Sharpe AH; Watts TH
    J Immunol; 2004 Nov; 173(10):5944-51. PubMed ID: 15528328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo.
    Ito T; Ueno T; Clarkson MR; Yuan X; Jurewicz MM; Yagita H; Azuma M; Sharpe AH; Auchincloss H; Sayegh MH; Najafian N
    J Immunol; 2005 Jun; 174(11):6648-56. PubMed ID: 15905503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preferential T cell expansion by artificial antigen presenting cells expressing 4-1BBL alone or in combination with CD80 or CD86.
    Habib-Agahi M; Jaberipour M; Phan TT; Searle PF
    Iran J Immunol; 2008 Sep; 5(3):136-47. PubMed ID: 18791280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Without CD4 help, CD8 rejection of pig xenografts requires CD28 costimulation but not perforin killing.
    Zhan Y; Brady JL; Sutherland RM; Lew AM
    J Immunol; 2001 Dec; 167(11):6279-85. PubMed ID: 11714791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of a VLA-2 (CD49b)-expressing effector T cell population by a cell-based neuroblastoma vaccine expressing CD137L.
    Yan X; Johnson BD; Orentas RJ
    J Immunol; 2008 Oct; 181(7):4621-31. PubMed ID: 18802064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Costimulatory ligand 4-1BBL (CD137L) as an efficient adjuvant for human antiviral cytotoxic T cell responses.
    Bukczynski J; Wen T; Ellefsen K; Gauldie J; Watts TH
    Proc Natl Acad Sci U S A; 2004 Feb; 101(5):1291-6. PubMed ID: 14745033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 4-1BB ligand, a member of the TNF family, is important for the generation of antiviral CD8 T cell responses.
    Tan JT; Whitmire JK; Ahmed R; Pearson TC; Larsen CP
    J Immunol; 1999 Nov; 163(9):4859-68. PubMed ID: 10528187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonreplicating recombinant vaccinia virus expressing CD40 ligand enhances APC capacity to stimulate specific CD4+ and CD8+ T cell responses.
    Feder-Mengus C; Schultz-Thater E; Oertli D; Marti WR; Heberer M; Spagnoli GC; Zajac P
    Hum Gene Ther; 2005 Mar; 16(3):348-60. PubMed ID: 15812230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antigen-presenting cells containing multiple costimulatory molecules promote activation and expansion of human antigen-specific memory CD8+ T cells.
    Yang S; Schlom J
    Cancer Immunol Immunother; 2009 Apr; 58(4):503-15. PubMed ID: 18690438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The capacity of the natural ligands for CD28 to drive IL-4 expression in naïve and antigen-primed CD4+ and CD8+ T cells.
    Bian Y; Hiraoka S; Tomura M; Zhou XY; Yashiro-Ohtani Y; Mori Y; Shimizu J; Ono S; Dunussi-Joannopoulos K; Wolf S; Fujiwara H
    Int Immunol; 2005 Jan; 17(1):73-83. PubMed ID: 15569772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD8+ cells and not CD4+ T cells are hyporesponsive to CD28- and CD40L-mediated activation in HIV-infected subjects.
    Vingerhoets J; Kestens L; Penne G; De Vuyst H; Vandenbruaene M; Pelgrom Y; Bosmans E; de Boer M; Kasran A; Azuma M; Colebunders R; Ceuppens JL; Vanham G
    Clin Exp Immunol; 1997 Mar; 107(3):440-7. PubMed ID: 9067514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.